$KTTA

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

MIAMI, Nov. 28, 2025 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp. ( "Pasithea" or the "Company" ) ( Nasdaq: KTTA. KTTAW ) , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis type 1-associated ...

Original reporting
GlobeNewswire · Pasithea
Published Nov 28, 2025, 2:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 28, 2025, 2:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock — source image
Decision brief

The 30-second read

$KTTANeutralLow
01

Why it matters

The public offering aims to fund ongoing clinical trials and expansion efforts. Market response is cautious, reflecting typical dilution effects.

02

Market read

Limited immediate trading impact; primarily relevant for biotech investors and stakeholders.

03

What to watch

Market may interpret the offering as a sign of confidence and future growth prospects, offsetting dilution concerns.

Timing: short-term

Background

Pasithea Therapeutics is a clinical-stage biotech developing neurofibromatosis treatments, with recent focus on PAS-004, a macrocyclic MEK inhibitor.

Company-level read

Ticker impact

$KTTANeutralMedium confidence
Context

Primary focus due to recent public offering and potential impact on stock valuation.

Expected impact

Minimal short-term fluctuation; potential slight downward pressure due to dilution, but offset by capital infusion.

Evidence & confidence

The offering size is moderate relative to the company's valuation, and market sentiment remains neutral. No significant technical signals or industry shifts are evident.

Market effects

Biotech sector may experience slight investor caution due to capital raising activities.

Limited regional impact; primarily affects US biotech stocks.

Low; specific to company and sector.

Counterpoint

The capital infusion could enable Pasithea to accelerate development, potentially leading to positive long-term valuation adjustments.

Key entities

  • Pasithea Therapeutics

    Biotech firm specializing in neurofibromatosis treatments.

Related articles

$KTTAMedAI 9/10

Pasithea's PAS-004 Receives FDA Orphan Drug Designation In Treating AL. Sclerosis

Pasithea Therapeutics (KTTA) said the U.S. FDA granted Orphan Drug Designation to PAS-004 for amyotrophic lateral sclerosis (ALS). The company said PAS-004 is a macrocyclic MEK inhibitor and is in Phase 1 trials in advanced cancer and Phase 1/1b trials in NF1-associated plexiform neurofibromas. Orphan status can bring tax credits, fee exemptions, and up to seven years’ exclusivity after approval.

$ETNMed

Eaton Gains on $7-Million Contract

Eaton (NYSE:ETN) said the U.S. Air Force Research Laboratory awarded it a $7 million, 24-month contract to use quantum computing, machine learning, and advanced visualization to improve power grid resilience and protection. The work, with Infleqtion and Penn State, targets detection and response to multiple concurrent physical and cyber threats, addressing NERC N-2 contingency requirements.

$XOMMed

ExxonMobil awards McDermott engineering work for Rovuma LNG

ExxonMobil Moçambique Limitada issued McDermott Energy Solutions (UK) a letter of intent for limited engineering and procurement work on Rovuma LNG Phase 1 midstream development. The award supports planning ahead of a final investment decision expected in 2026. Rovuma LNG targets 12 modular trains totaling 18.6 mtpa, with start-up in 2031. ExxonMobil says the 30-year project could generate about $150B in revenues for Mozambique’s government.

$ESLTMed

Serbia to open joint UAV factory with Elbit in September

Serbia President Aleksandar Vucic said Serbia will open a joint UAV factory with Elbit Systems, with inauguration expected Sept 15-20. Elbit will hold 51% and Serbia’s state arms firm SDPR 49%. The factory relates to a five-year contract covering precision rockets and unmanned systems, plus ISTAR, digitization and upgrades.

$NOCMed

The Pentagon is urging defense contractors to urgently ramp up weapons production – WP

The U.S. Department of Defense, according to The Washington Post, asked defense contractors to submit within 21 days production and delivery schedules for critical systems, citing depleted stockpiles. CSIS estimates cite heavy early use of missiles and falling Patriot and THAAD inventories. The Pentagon is working with Northrop Grumman and Lockheed Martin, including a $58.6B deal to triple PAC-3 output by 2030, pending a stalled $1.15T defense budget.

$LMTMed

Pentagon pushes military contractors to accelerate production amid shortages after war on Iran

The Pentagon ordered US defense contractors to submit within 21 days plans to accelerate production of missiles and interceptors amid shortages after the first month of strikes against Iran. It cited depleted Patriot and THAAD inventories and said framework agreements with Lockheed Martin and Northrop Grumman target PAC-3 and THAAD output. Lockheed Martin received a contract up to $58.6B to triple PAC-3 production by 2030.